Bayer
Pharmaceutical Giants J&J and Bayer Announce Layoffs of Nearly 300 Employees in New Jersey
Johnson & Johnson, Bayer, layoffs, New Jersey, pharmaceutical industry, job cuts
Big Pharma’s Layoff Wave Continues in New Jersey: J&J and Bayer Announce Significant Job Cuts
Big Pharma layoffs, New Jersey, Johnson & Johnson, Bayer, pharmaceutical industry restructuring
Biopharma Leaders Navigate AI ‘Hype Cycle’: Bayer, Daiichi Sankyo, and argenx Share Insights on AI Implementation in Marketing
AI in biopharma marketing, Bayer, Daiichi Sankyo, argenx, AI implementation, biopharma industry, AI hype cycle
Bayer Seeks to Broaden Nubeqa’s Use in Prostate Cancer with Chemotherapy-Free Treatment Option
Nubeqa, Bayer, prostate cancer, chemotherapy-free, label expansion, ARANOTE trial, darolutamide, androgen deprivation therapy (ADT), metastatic hormone-sensitive prostate cancer (mHSPC)
Elinzanetant Demonstrates Sustained Efficacy Over One Year in Managing Menopausal Vasomotor Symptoms
Elinzanetant, Menopause, Vasomotor Symptoms, Sleep Disturbances, Non-Hormonal Treatment, Bayer
Roivant Sciences Acquires Experimental Pulmonary Hypertension Drug Mosliciguat from Bayer
Roivant Sciences, Pulmovant, Bayer, Mosliciguat, Pulmonary Hypertension, PH-ILD, Interstitial Lung Disease
WCLC24 Highlights: ArriVent’s Drug Aims to Address Tagrisso’s Limitations; Boehringer and Bayer Share Data on HER2-Mutated Lung Cancer
WCLC24, ArriVent, Tagrisso, Boehringer, Bayer, HER2-mutated lung cancer, Lung cancer treatment, EGFR-mutated lung cancer
Bayer’s Kerendia Demonstrates 16% Reduction in Cardiovascular Risk for Heart Failure Patients
Bayer, Kerendia, cardiovascular risk, heart failure, finerenone, Phase III trial, FINEARTS-HF, MOONRAKER
Bayer’s Asundexian Fails to Prevent Strokes, Jeopardizing $5.5 Billion Blockbuster Hopes
Bayer, asundexian, stroke prevention, atrial fibrillation, Factor XI inhibitors, clinical trials
Bayer and NextRNA Therapeutics Collaborate on $547 Million Deal to Develop Innovative Cancer Therapies Targeting Long Non-Coding RNAs
Bayer, NextRNA Therapeutics, lncRNA, small molecules, cancer, oncology, partnership, drug development